Biblio

Found 16 results
Filters: Author is Streicher, John M and Keyword is Humans  [Clear All Filters]
2023
Varga BR, Streicher JM, Majumdar S.  2023.  Strategies towards safer opioid analgesics-A review of old and upcoming targets.. Br J Pharmacol. 180(7):975-993.
2021
Tanguturi P, Pathak V, Zhang S, Moukha-Chafiq O, Augelli-Szafran CE, Streicher JM.  2021.  Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists.. Molecules. 26(21)
2020
LaVigne J, Keresztes A, Chiem D, Streicher JM.  2020.  The endomorphin-1/2 and dynorphin-B peptides display biased agonism at the mu opioid receptor.. Pharmacol Rep. 72(2):465-471.
2019
Olson KM, Duron DI, Womer D, Fell R, Streicher JM.  2019.  Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids.. PLoS One. 14(6):e0217371.
Streicher JM.  2019.  The Role of Heat Shock Proteins in Regulating Receptor Signal Transduction.. Mol Pharmacol. 95(5):468-474.
2018
Streicher JM, Bilsky EJ.  2018.  Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications.. J Pharm Pract. 31(6):658-669.
Shah N, Kumar S, Zaman N, Pan CC, Bloodworth JC, Lei W, Streicher JM, Hempel N, Mythreye K, Lee NY.  2018.  TAK1 activation of alpha-TAT1 and microtubule hyperacetylation control AKT signaling and cell growth.. Nat Commun. 9(1):1696.
2017
Lei W, Mullen N, McCarthy S, Brann C, Richard P, Cormier J, Edwards K, Bilsky EJ, Streicher JM.  2017.  Heat-shock protein 90 (Hsp90) promotes opioid-induced anti-nociception by an ERK mitogen-activated protein kinase (MAPK) mechanism in mouse brain.. J Biol Chem. 292(25):10414-10428.
Keresztes A, Streicher JM.  2017.  Synergistic interaction of the cannabinoid and death receptor systems - a potential target for future cancer therapies? FEBS Lett. 591(20):3235-3251.
2016
Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE.  2016.  17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.. ACS Chem Neurosci. 7(3):297-304.
2015
Frankowski KJ, Slauson SR, Lovell KM, Phillips AM, Streicher JM, Zhou L, Whipple DA, Schoenen FJ, Prisinzano TE, Bohn LM et al..  2015.  Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.. Bioorg Med Chem. 23(14):3948-56.
2014
Zhang Y, Braithwaite A, Yuan Y, Streicher JM, Bilsky EJ.  2014.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.. Eur J Pharmacol. 736:124-30.
2013
Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, Madoux F et al..  2013.  Development of functionally selective, small molecule agonists at kappa opioid receptors.. J Biol Chem. 288(51):36703-16.
2012
Béguin C, Potuzak J, Xu W, Liu-Chen L-Y, Streicher JM, Groer CE, Bohn LM, Carlezon WA, Cohen BM.  2012.  Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.. Bioorg Med Chem Lett. 22(2):1023-6.
2004
Huan J-Y, Streicher JM, Bleyle LA, Koop DR.  2004.  Proteasome-dependent degradation of cytochromes P450 2E1 and 2B1 expressed in tetracycline-regulated HeLa cells.. Toxicol Appl Pharmacol. 199(3):332-43.
2002
Bethea CL, Lu NZ, Gundlah C, Streicher JM.  2002.  Diverse actions of ovarian steroids in the serotonin neural system.. Front Neuroendocrinol. 23(1):41-100.